Written By: Ethan Copple, Ph.D.
Pull on almost any thread of the modern industrial economy and you will find a nitrile glove at the end of it. Surgeons, semiconductor technicians, food inspectors, pharmaceutical chemists, rare earth processors, auto assembly workers, oil and gas field crews, and the soldiers handling energetics at DoD facilities all wear them to perform their essential tasks. They are not a medical product that happens to have other uses. They are a universal industrial input, as foundational to modern production as steel or electricity, and nearly as invisible until they are gone.
The United States consumes over 100 billion nitrile gloves annually, imports nearly 99% of them, and produces under 1% domestically as of early 2026 [1], [2]. Though many believe there was a self-correction after the woes of the pandemic, foreign nitrile glove reliance has continued to be a structural shortfall. This shortcoming has outlasted two administrations, survived roughly $574 million in dedicated federal investment, and persisted despite repeated warnings from industry and government watchdogs alike. The country was within reach of a domestic solution. Then the funding was pulled..
The case for reshoring American manufacturing has been made repeatedly, most recently by Scott Maier and Garrett Murch in American Affairs [1]. This piece does not re-litigate the underlying risk so much as examine why current efforts continue to fail, why the failure matters across the entire industrial economy, and what a functional policy framework for reshoring would actually look like.
The Supply Chain Is More Exposed Than It Appears
Finished nitrile gloves arrive from Malaysia, Thailand, and Vietnam, which the current policy consensus has treated as a “friend-shoring” success. This framing is wrong. The raw materials, acrylonitrile and butadiene, the precursors to nitrile butadiene rubber (NBR), flow almost exclusively from China, where producers leverage subsidized oil from Russia and Iran to undercut world market prices. China effectively controls an estimated 90% of the effective global market through raw material dominance alone, regardless of where gloves are dipped [3], [4]. Shifting final assembly to Malaysia while leaving the NBR supply chain intact does not reduce U.S. exposure. In many cases, “friend-shoring” makes our friendly trade partners a Chinese transit stop.
China has a documented history of weaponizing strategic commodity exports during periods of tension. Its behavior during the COVID-19 pandemic, when it hoarded and restricted PPE exports, established the template [5], [6]. The Strategic National Stockpile held roughly a 10-day supply of gloves as of late 2025, according to Maier [7]. The pandemic pointed to the inadequacy of then-current stockpiling, with only 2 million gloves of the HHS goal of 4.5 billion actually stockpiled [8]. A supply cutoff might give U.S. industry weeks or possibly just days to adapt.
The Modern World Is Built with Nitrile Gloves
Healthcare medical-adjacent sectors are the most visible use case, consuming roughly 50 to 60% of U.S. demand [1]. Surgeons, nurses, emergency responders, long-term care workers, and biotech and pharmaceutical manufacturing rely on gloves for every patient contact. During the 2020 and 2021 shortages, hospitals resorted to reusing single-use gloves to stretch limited supply, directly increasing patient and care provider risks and operational chaos [9], [10]. FDA inspections have flagged defects in imported gloves, including tearing and contamination, documenting how quality degradation compounds scarcity [4]. But healthcare is where the dependency is most visible, not where it ends.
The other 40 to 50% of demand spans nearly every productive sector of the economy, and a disruption would cut across all of them simultaneously.
Advanced manufacturing and semiconductors. Semiconductor fabs require cleanroom environments where even trace contamination can ruin a wafer run. The CHIPS Act has catalyzed over $640 billion in investment toward domestic chip production [11], [12], [13]. Every one of those facilities runs on a continuous supply of nitrile gloves. A shortage does not slow chip production. It stops it. Defense electronics, AI compute, and the entire stack of reindustrialization ambitions that depend on domestic semiconductor capacity share this single-point vulnerability.
Critical minerals and rare earth processing. Rare earth refining and battery material processing require direct handling of hazardous chemicals and heavy metals. Workers cannot safely process lithium, cobalt, or rare earth oxides without chemical-resistant barrier protection. As the Inflation Reduction Act accelerates domestic mining and processing, glove supply becomes a rate-limiting input for energy independence goals.
Pharmaceuticals and biotech. Sterile drug manufacturing and active pharmaceutical ingredient (API) production require controlled environments. The U.S. relies on China for near-monopoly shares of specific critical inputs, including 92% of penicillin, 99% of prednisone, and the majority of antibiotic precursors. India, which supplies the bulk of U.S. generics, itself depends on China for 70-80% of its own API inputs [14], [15]. Glove disruptions would not just slow pharmaceutical production. They would force facility shutdowns under FDA contamination rules, cascading into drug shortages on top of glove shortages.
Food processing. The food supply chain depends on nitrile gloves at every stage where human hands contact product, from slaughterhouses to packaging lines. A shortage does not produce an abstract supply chain problem. It produces contamination events, regulatory shutdowns, and public health crises.
Automotive, aerospace, and precision manufacturing. Assembly workers handling adhesives, lubricants, and precision components rely on gloves for chemical protection and to prevent skin oils from contaminating finished surfaces. In aerospace, a contaminated component can mean a grounded aircraft. In automotive, it means rework and warranty exposure.
Oil, gas, and chemical handling. Field crews and refinery workers handling hydrocarbons and industrial chemicals require chemical-resistant gloves as basic safety equipment. An extended shortage would create OSHA compliance crises across the energy sector.
Defense and energetics. The Department of Defense has identified gloves as a reshoring priority specifically because energetics production, including explosives, requires them for safe handling [3]. A military that cannot source adequate barrier protection for its munitions workers has a readiness problem that no weapons system can compensate for.
The logic that makes nitrile gloves seem unimportant, their low unit cost and high ubiquity, is exactly what makes a disruption so dangerous. When a $0.03 glove is a required input for ten different industries running simultaneously, and the supply of all of them runs through the same Chinese-controlled raw material chain, a single geopolitical decision in Beijing can halt American production across the board.
Not sequentially. All at once.
Why Current Efforts Have Not Worked
The federal government has spent approximately $1.5 billion reshoring PPE broadly since 2020, with roughly $574 million directed specifically at nitrile gloves [16]. Actual domestic production remains under 1% of national needs. The gap between investment and outcome is not accidental. It reflects compounding structural failures, and one story captures them all.
The Blue Star NBR failure is the clearest case study in how not to reshore a supply chain.
In the years following COVID-19, Blue Star NBR, founded by Scott Maier, secured federal backing to build a vertically integrated glove manufacturing facility in Wytheville, Virginia. The plant was designed to produce NBR from domestic raw materials sourced off the Gulf Coast and then dip finished gloves on site, a fully domestic supply chain that would have put the U.S. in genuine control of a meaningful share of its own production. Construction began. The state of Virginia committed resources. Local investment followed. For a period, the country had something it had lacked since the pandemic exposed the vulnerability: a credible path out of import dependency [17], [18].
Then the funding was pulled.
Federal follow-through financing did not materialize. The Development Finance Corporation, which had been designated as the central mechanism for exactly this kind of domestic industrial lending, had not issued a single loan under its PPE mandate as of October 2021 [19]. A 2025 House testimony document confirmed the DFC had taken no additional actions to address that finding [20]. The result was predictable. Construction stalled. The facility sits partially built. The state and local investments made in good faith to match federal commitments are stranded. The jobs never materialized. And the country is exactly where it was in 2020: dependent on Chinese-controlled supply chains for a product every sector of its economy requires daily.
In March 2026, the situation deteriorated further. Maier posted on X that he had received official word that the U.S. government “does not see the need to support a domestic nitrile glove industry,” and that Blue Star’s “reindustrialization journey is coming to an end” [21], [22]. Speaking on Breitbart News Saturday days later, he disclosed that the facility that is 80 to 85 percent complete would fulfill its remaining contract obligations through July 2026, after which the equipment would most likely be dismantled and sold to overseas buyers [23]. He also flagged a new and compounding risk: with the Strait of Hormuz closed due to the conflict with Iran, China is unable to source the raw materials needed to supply Malaysian manufacturers, and Malaysia has warned its own government of imminent production shutdowns. Maier estimates the world is “probably 60 to 90 days from having glove shortages again.” The country that was 80 percent of the way to a domestic solution is now watching that solution be sold off, piece by piece, to the same overseas market it was built to replace.
This is not a story about a company that failed to execute. It is a story about a government that made a commitment, attracted private and state capital on the basis of that commitment, and then walked away. The rug was pulled not through any single dramatic decision but through the slower institutional failure of a financing agency that proved unable to do its job. The lesson for any manufacturer considering domestic glove production is obvious and chilling: federal support is not bankable.
Market distortions that tariffs have only partially addressed. Chinese glove producers flood markets at $17 to $18 per 1,000 pieces, well below the $20 to $21 range at which U.S. production is viable [1], [24]. Section 301 tariffs on finished gloves rose to 50% in 2025 and 100% in 2026, which moves the needle. But NBR precursors largely escape those duties, enabling continued circumvention through third-country processing. The “friend-shored” appearance of Malaysian production masks the same underlying exposure.
No binding procurement mandates. CMS has proposed reimbursement incentives for domestically sourced gloves [25]. Federal agencies have not mandated minimum domestic sourcing percentages. Without demand-side commitments from the government’s own purchasing apparatus, private capital has no reliable floor to invest against on a $0.03 commodity with thin margins.
Coordination compounds all of this. Investments across HHS, DFC, DoD, and DPA have operated in silos, without the supply chain mapping that would identify where intervention actually creates leverage.
A Policy Framework That Would Work
Reshoring nitrile gloves requires treating the supply chain as a system, not a collection of individual procurement decisions. Building on Maier [1], [3], the following six-part framework proposed by the Institute for American Manufacturing and Technology addresses each structural failure.
1. A dedicated federal reshoring program. A federal program of roughly $2 billion over five years, structured as grants, low-interest loans, and tax credits targeting domestic NBR and glove production, would address the funding gaps documented above. Priority should go to vertically integrated facilities, those capable of producing NBR through finished gloves, located in strategic domestic hubs. The target is 50% domestic supply by 2030. This would directly address the funding commitment failures that have stranded partial construction like the Virginia facility.
2. Extend tariffs to NBR precursors and close circumvention loopholes. Section 301 duties should cover acrylonitrile and butadiene precursors, starting at 50% in 2026 and rising to 100% by 2028. Anti-circumvention enforcement must close the third-country rerouting gap that currently allows Chinese raw material dominance to persist under the cover of Malaysian final assembly.
3. Mandate federal procurement sourcing floors. Federal agencies, Medicare, and defense contractors should be required to source a growing percentage of gloves domestically, reaching 50% by 2028. CMS reimbursements for domestically produced gloves should be tied to performance benchmarks, not just declared capacity. Integration with the Defense Production Act would establish stockpiling requirements tied to actual output, not inoperable facilities [25].
4. Fund R&D and workforce infrastructure. Allocate $500 million for innovation grants in sustainable glove chemistry and manufacturing automation, paired with federal apprenticeship and training programs that serve regional manufacturing hubs. Automation is what makes U.S. production cost-competitive against subsidized Asian labor. Workforce pipelines are what sustain it.
5. Streamline regulatory pathways and mandate supply chain transparency. Accelerate FDA approval timelines for domestic glove facilities. Designate nitrile gloves as critical infrastructure under Commerce Department authority. Require annual supply chain assessments with full systems mapping, including geopolitical exposure through raw material dependencies. Annual reporting requirements on actual production, not described capacity, would give Congress and DFC the oversight tools the GAO found were absent.
6. Build regional public-private coalitions modeled on semiconductor policy. Fund regional manufacturing hubs through federal-state-industry partnerships that pilot nearshoring and vertical integration at scale. Groups like the Coalition for a Prosperous America can provide policy coordination and advocacy infrastructure. The CHIPS Act demonstrated that this model can generate hundreds of billions in private co-investment when federal commitment is credible and sustained.
The Case for Acting Now
Supply chains do not hold at some stable equilibrium waiting for policy to catch up. They drift. The longer Chinese dominance over NBR precursors goes unchallenged, the deeper the structural dependency becomes and the higher the cost of reversing it. The 2020 disruptions demonstrated what current U.S. stockpiles look like when global chains fail under stress. The next disruption will not require a pandemic. It will be due to a geopolitical decision made in Beijing.
The Blue Star experience has also poisoned the well. Every manufacturer who watched that facility stall knows that federal commitments in this space are not reliable. Rebuilding the credibility to attract private capital requires not just new legislation but demonstrated follow-through, which means any future reshoring program would need appropriations that are locked in, not contingent on agency discretion.
The CHIPS Act showed that the U.S. is capable of decisive industrial policy when it treats an input as genuinely strategic. The argument for nitrile gloves is stronger than the argument for chips in one respect: gloves are not critical to one industry. They are critical to nearly all of them. Chips matter for computing. Gloves matter for chips, for food, for medicine, for energy, for defense, and for every other productive sector running simultaneously. A country that cannot supply this input domestically has not just a healthcare vulnerability. It has a single point of failure wired into every facet of manufacturing and to the entire economy.
The analysis points to a clear set of conditions for closing this vulnerability: a dedicated federal reshoring program with funding mechanisms that do not route through the DFC’s discretionary authority, and conversion of procurement encouragement into enforceable sourcing mandates by federal agencies. Industry leaders across semiconductors, pharmaceuticals, food processing, and advanced manufacturing should commit to domestic sourcing targets, creating the demand floor that private investment requires. Researchers should quantify the cross-sector disruption costs that would follow a supply cutoff, building the evidence base that policy arguments currently lack.
The dependency is documented. The solution framework exists. The country almost had a domestic manufacturer. It let that slip away once. The question is whether policymakers are willing to make the credible, sustained commitment required to get there again.
